RxDoctor Payments Data

Ria Parcellano, MD

Geriatric Medicine · Schaumburg, ILNPI 1366708117

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $715 of the $988 with a category attached, or 72.4%. TG Therapeutics, Inc. accounts for 72.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $715 and has fallen 97.9% since, to $15 in 2025.

$988in general payments, 2019–2025

Across 18 payments — averaging $54.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • TG Therapeutics, Inc.$715
  • AstraZeneca$50
  • Novo Nordisk$37
  • Johnson & Johnson$31
  • Pfizer$21
  • Hologic Sales And Service, LLC$20
  • plus $114 from 7 others

What the payments were for

  • Consulting fees$71572%
  • Food & beverage$27328%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$988 in reported general payments places this provider in the 80th percentile of 147 geriatric medicine providers in Illinois.

See all geriatric medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$81,706
Medicare patients
171
Services billed
1,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$41,743
JardianceEmpagliflozin24$38,992
JanuviaSitagliptin Phosphate23$31,650
EliquisApixaban15$21,057
Incruse ElliptaUmeclidinium Bromide26$9,607
Breo ElliptaFluticasone/Vilanterol11$7,339
Rosuvastatin Calcium118$3,118
Albuterol Sulfate HfaAlbuterol Sulfate77$2,464
Losartan Potassium185$2,120
Atorvastatin Calcium203$1,984
Wixela InhubFluticasone Propion/Salmeterol12$1,839
Metoprolol Succinate95$1,816
Levothyroxine Sodium118$1,685
Amlodipine Besylate163$1,248
Lisinopril110$1,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$41,74340 claims
Boehringer IngelheimJardiance$16$38,99224 claims
PfizerEliquis$21$21,05715 claims
GSKIncruse Ellipta, Breo Ellipta$16$16,94537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 147 geriatric medicine providers in Illinois.

Other geriatric medicine in Schaumburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →